Generation Bio (GBIO)
(Delayed Data from NSDQ)
$3.18 USD
-0.07 (-2.15%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Generation Bio Co. [GBIO]
Reports for Purchase
Showing records 1 - 20 ( 46 total )
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Out with the Old (ce), In with the New (iq)DNA
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Potential Generational Shift in Genetic Medicines
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Moderna Deal Helps Get Closer to Proof of Concept
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Heading Into a New Generation with Two Novel ctLNPs
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D